Ardelyx is trading 5.11% down at $3.44, as broader market weakness pressures risk-sensitive equities. - The Nasdaq is down 1.03% and the S&P 500 is down 0.55%, while biotech is up 2.07%. - Securities-fraud lawsuit reminders remain an overhang, alleging Ardelyx cut IBSRELA guidance and withdrew long-term XPHOZAH guidance in August. - No new company-specific catalyst was found for September 23, 2026.